Kips Bay Medical (NASDAQ: KIPS) today announced that the United States Patent and Trademark Office (USPTO) has issued to the Company patent number 7,998,188, titled “Compliant Blood Vessel Graft,” which includes eleven permitted claims covering the Company’s core eSVS ® MESH technology, and represents the first patent obtained in the United States covering this technology. The USPTO has also issued a Notice of Allowance approving a second patent application, titled “Compliant Venous Stent,” which includes three claims related to the eSVS MESH design. “This is great news for the Company,” stated Manny Villafaña, Chairman and Chief Executive Officer. “We believe that the issuance of this patent and the approval of this patent application provide the foundation for very strong and broad-based protection for our eSVS MESH. These are important milestones in the development and growth of our intellectual property portfolio and securing our leadership position in cardiovascular bypass surgery.” At present, the Company possesses issued patents in Japan and Canada covering the eSVS MESH. In addition, it has received a Notice of Allowance from the European Patent Office and is presently engaged in the grant phase to validate the European patent in eight European Countries. The company is pursuing additional patent applications which are pending in the United States and in strategic countries world-wide. About Kips Bay Medical Kips Bay Medical, Inc., founded in 2007 and headquartered in Minneapolis, Minnesota, is a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, or eSVS MESH for use in coronary artery bypass grafting surgery. Our eSVS MESH is a nitinol mesh sleeve that, when placed over a saphenous vein graft during CABG surgery, is designed to improve the structural characteristics and long-term performance of the saphenous vein graft. Additional information about Kips Bay Medical, Inc. can be found at www.kipsbaymedical.com.